Aclaris Therapeutics

$18.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-4.57%) Today

+$0.05 (+0.28%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ACRS and other stocks, options, and ETFs commission-free!

About ACRS

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA. The listed name for ACRS is Aclaris Therapeutics, Inc. Common Stock.

CEO

Neal S. Walker

Employees

Headquarters

Malvern, Pennsylvania

Founded

2012

Market Cap

771.26M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

11.84M

High Today

$24.27

Low Today

$17.71

Open Price

$19.98

Volume

20.42M

52 Week High

$24.27

52 Week Low

$0.70

Collections

ACRS News

MarketWatchJan 19

Aclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial

Shares of Aclaris Therapeutics Inc. ACRS, +208.42% skyrocketed more than 200% toward a 2 1/2-year high, on massive volume, in midday trading Tuesday, after the

ACRS Earnings

-$1.24

-$0.83

-$0.41

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, Pre-Market